Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Qishen Yiqi Dripping Pills for chronic heart failure with reduced ejection fraction due to coronary heart disease
CTR20262484Phase 3Active
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of qishen yiqi dripping pills in heart failure with reduced ejection fraction (HFrEF), coronary arteriosclerosis, sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
qishen yiqi dripping pills
03
Conditions
heart failure with reduced ejection fraction (HFrEF)coronary arteriosclerosis
Beyond the preview
Go deeper on CTR20262484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262484.